

Pharmacokinetic and Pharmacodynamic Interaction Between Allopurinol and Probenecid in Patients with Gout

SOPHIE L. STOCKER, GARRY G. GRAHAM, ANDREW J. McLACHLAN, KENNETH M. WILLIAMS, and RICHARD O. DAY

ABSTRACT. Objective. To investigate the pharmacokinetic and pharmacodynamic interaction between probenecid and oxypurinol (the active metabolite of allopurinol) in patients with gout.

Methods. This was an open-label observational clinical study. Blood and urine samples were collected to measure oxypurinol and urate concentrations. We examined the effects of adding probenecid to allopurinol therapy upon plasma concentrations and renal clearances of urate and oxypurinol.

Results. Twenty patients taking allopurinol 100–400 mg daily completed the study. Maximum coadministered doses of probenecid were 250 mg/day ($n = 1$), 500 mg/day ($n = 19$), 1000 mg/day ($n = 7$), 1500 mg/day ($n = 3$), and 2000 mg/day ($n = 1$). All doses except the 250 mg daily dose were divided and dosing was twice daily. Estimated creatinine clearances ranged from 28 to 113 ml/min. Addition of probenecid 500 mg/day to allopurinol therapy decreased plasma urate concentrations by 25%, from mean 0.37 mmol/l (95% CI 0.33–0.41) to mean 0.28 mmol/l (95% CI 0.24–0.32) ($p < 0.001$); and increased renal urate clearance by 62%, from mean 6.0 ml/min (95% CI 4.5–7.5) to mean 9.6 ml/min (95% CI 6.9–12.3) ($p < 0.001$). Average steady-state plasma oxypurinol concentrations decreased by 26%, from mean 11.1 mg/l (95% CI 5.0–17.3) to mean 8.2 mg/l (95% CI 4.0–12.4) ($p < 0.001$); and renal oxypurinol clearance increased by 24%, from mean 12.7 ml/min (95% CI 9.6–15.8) to mean 16.1 ml/min (95% CI 12.0–20.2) ($p < 0.05$). The additional hypouricemic effect of probenecid 500 mg/day appeared to be lower in patients with renal impairment.

Conclusion. Coadministration of allopurinol with probenecid had a significantly greater hypouricemic effect than allopurinol alone despite an associated reduction of plasma oxypurinol concentrations. Australian Clinical Trials Registry ACTRN012606000276550. (First Release Feb 1 2011; J Rheumatol 2011;38:904–10; doi:10.3899/jrheum.101160)

Key Indexing Terms:

ALLOPURINOL
PHARMACOKINETICS

PROBENECID

GOUT

URATE
PHARMACODYNAMICS

From the Faculty of Pharmacy, University of Sydney; Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital; School of Medical Sciences, University of New South Wales; Centre for Education and Research on Ageing, Concord Hospital; and St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.

Supported by an Arthritis Australia National Research Grant and a NH&MRC Program Grant 568612.

S.L. Stocker, BSc, Faculty of Pharmacy, University of Sydney, Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital; G.G. Graham, PhD, Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, School of Medical Sciences, University of New South Wales; A.J. McLachlan, BPharm, PhD, Faculty of Pharmacy, University of Sydney, Centre for Education and Research on Ageing, Concord Hospital; K.M. Williams, PhD, Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, School of Medical Sciences, University of New South Wales; R.O. Day, MD, FRACP, Department of Clinical Pharmacology and Toxicology, St. Vincent's Hospital, School of Medical Sciences, St. Vincent's Clinical School, University of New South Wales.

Address correspondence to Prof. R. Day, Department of Clinical Pharmacology, St. Vincent's Hospital, NSW, 2010 Sydney, Australia. E-mail: r.day@unsw.edu.au

Accepted for publication December 8, 2010.

Allopurinol is widely used for the treatment of hyperuricemia and gout. Allopurinol has a short half-life (1.1 ± 0.3 h) in blood and is rapidly metabolized to its active metabolite, oxypurinol, which has a considerably longer half-life (23 ± 7 h)¹. Oxypurinol is largely responsible for the plasma urate reduction^{2,3}. Current treatment guidelines for gout recommend maintaining plasma urate concentrations below 0.30 mmol/l⁴ to reduce the frequency of recurrent attacks of gout^{5,6} and to increase the rate of dissolution of tophi^{7,8}.

Probenecid is an effective hypouricemic agent that inhibits active renal reabsorption of urate by the transporter URAT1 in proximal tubular epithelial cells^{9,10,11}. In patients with renal impairment the linked hypouricemic and uricosuric effect of probenecid is reduced^{12,13,14,15}.

Concomitant use of allopurinol and probenecid has been advocated in patients with tophaceous gout or for patients responding inadequately to monotherapy with allopurinol.

nol^{16,17}. The rationale for the combination is that allopurinol inhibits the production of urate while probenecid increases the elimination of urate. However, there has been limited and somewhat conflicting data on the hypouricemic effect of this combination^{18,19,20}. Probenecid has been shown to decrease plasma oxypurinol concentrations by 50% in healthy volunteers¹⁸, by increasing the renal clearance of oxypurinol²¹. However, despite this reduction of plasma concentrations of oxypurinol, studies in healthy volunteers¹⁸ and in patients with gout with adequate renal function (estimated creatinine clearance > 50 ml/min)¹⁹ have demonstrated a greater urate-lowering effect of the combination than use of either allopurinol or probenecid alone¹⁸, although the hypouricemic effect of the combination was less marked in another study that included gouty patients with renal impairment²⁰.

We investigated the effects of the addition of probenecid on the plasma concentrations of urate and the pharmacokinetics of oxypurinol in patients with gout, and varying degrees of renal function, who were being treated with allopurinol.

MATERIALS AND METHODS

Study population. Patients aged ≥ 18 years with a confirmed diagnosis of gout (American Rheumatism Association criteria²²) and who had been receiving allopurinol at a stable dose for at least 1 month were eligible for participation. They were recruited by referrals from rheumatologists on St. Vincent's Hospital Sydney campus and advertisements in the hospital.

All patients provided written informed consent. The study was performed in accord with good clinical research practice standards and in accord with the Declaration of Helsinki, 1996. The study was approved by the St. Vincent's Hospital Human Ethics Committee (H06/141) and registered in the Australian Clinical Trials Registry (ACTRN-01260-6000276550).

Study design. This was an observational open-label prospective clinical study conducted between April 2008 and August 2009 in patients with gout who were being treated with allopurinol.

Patients attended a screening visit, then a first or baseline visit if eligible and within 14 days of the screening visit. Subsequent visits were 1–3 weeks apart with the number of visits determined by the plasma concentrations of urate achieved up to a maximum of 5 visits. The last of these visits was designated the final visit, which was followed by an exit visit within 7 days.

Patients continued their baseline, daily dose of allopurinol as prescribed by their referring physician throughout the study period. Daily doses of allopurinol ranged from 100 to 400 mg/day and all patients were dosed once daily. After the first visit patients were dosed to steady-state (minimum 7 days) with probenecid 250 mg twice daily or once daily if the patient's estimated creatinine clearance was < 50 ml/min²³ (Figure 1). This creatinine clearance cutoff was chosen as it identifies a subgroup of patients where most clinicians consider probenecid to be less effective, a view supported by most guidelines. The dose of probenecid was increased at intervals of 1 to 3 weeks to a possible maximum of 2 g daily or until plasma concentrations of urate were ≤ 0.30 mmol/l. Patients with severe tophaceous gout were included in the study and dosed with probenecid even if their plasma urate concentrations were ≤ 0.30 mmol/l because lowering the plasma urate as much as possible was considered to be good clinical practice. Concomitant low-dose colchicine 0.5 to 1.0 mg/day depending on renal function (n = 18) or a nonsteroidal antiinflammatory drug (naproxen, ibuprofen; n = 2) was prescribed for the duration of the study in all patients




Figure 1. Disposition of gout patients in the study and probenecid dosing rates.

as prophylaxis against acute attacks of gout. Patients were allowed an unrestricted diet throughout the study but were asked to abstain from alcohol and caffeine-containing beverages for 12 h prior to each study visit.

A heparinized venous blood sample (8 ml) was obtained just before or at least 4 hours after the last dose of allopurinol. At each study visit (including screening and exit visits) patients provided a timed (2 h) urine collection, starting 1 hour prior to and finishing 1 hour after collection of the blood sample. Plasma was separated and stored at −20°C for analysis of urate, oxypurinol, and probenecid concentrations. Urine samples were collected for determination of oxypurinol, urate, and creatinine concentrations. Routine hematological, biochemical, and urine tests were conducted at the screening and exit visits. Patients were supplied with a diary to record time of dosing of all gout medications, including the intermittent use of medications for any joint pain. Dosing details of any concomitant medications were also recorded. After discharge from the study, a letter summarizing the patient's study results and recommendations regarding their gout management was sent to their primary care physician. Any adverse effects were documented.

Oxypurinol and probenecid assays. Plasma concentrations of oxypurinol

and probenecid were analyzed using validated high-performance liquid chromatography methods¹⁸. Concentrations of oxypurinol in urine were measured by LC-MS/MS²⁴. Adherence was established by examining plasma drug concentrations.

Pharmacokinetic and pharmacodynamic analysis. Renal clearances of oxypurinol [$CL_{R(OXY)}$], urate [$CL_{R(UA)}$], and creatinine [$CL_{R(CR)}$] were calculated from the 2 h urine collections according to $CL_R = U \cdot V/P$, where U is urinary concentration (mmol/l), V is the rate of production of urine (ml/min), and P is the plasma concentration of the compounds (mmol/l). Creatinine clearance was also estimated using the Cockcroft-Gault equation based on lean body weight²³. In order to account for renal function and its effects on renal clearance of urate and oxypurinol, the fractional renal clearances of urate ($CL_{R(UA/CR)}$) and oxypurinol ($CL_{R(OXY/CR)}$) were estimated from the quotient of their renal clearances and the renal clearance of creatinine for each participant. A fractional renal clearance of urate < 0.06 was considered low²⁵. The mean steady-state plasma oxypurinol concentrations ($C_{av,ss}$) and apparent total-body clearance of oxypurinol (CL/F) were estimated using nonlinear mixed-effects modeling (implemented by NONMEM version 6.1.0; ICON Development Solutions, NONMEM 7 Project Team; Ellicott City, MD, USA) and a one-compartment pharmacokinetic model with first-order absorption and elimination.

Statistical analyses. All data are presented as means and 95% confidence intervals. Paired t tests or one-way analysis of variance tests with repeated measures were used to compare pharmacokinetic (oxypurinol disposition) and pharmacodynamic (plasma urate concentrations) data while taking allopurinol alone and the combination of allopurinol and probenecid (500 or 1000 mg/day). Statistical analyses were not conducted on the data from patients receiving 1.5 or 2 g probenecid daily because of low subject numbers in these groups. Statistical analyses were conducted using GraphPad version 5 software (GraphPad Software, San Diego, CA, USA).

RESULTS

Patient characteristics. Thirty-one gout patients taking allopurinol were screened and gave consent to enter the study, but only 20 of these patients went on to receive concomitant doses of probenecid as 6 had plasma urates < 0.30 mmol/l, 1 failed pathology screening, and 4 did not return for a second visit (Figure 1). All patients were male and allopurinol doses were 100 mg/day (n = 3), 200 mg/day (n = 4), 300 mg/day (n = 12), or 400 mg/day (n = 1) and all doses were taken once daily. Most patients were receiving other drugs, cholesterol-lowering drugs being the most common, and some took medicines known to affect plasma urate concentrations (Table 1). These concomitant medicines were continued without change of dose throughout the study period. Twelve patients had had gout for < 10 years; 2 patients reported having gout for over 20 years. Five patients had tophi. More than half the patients had experienced 2 or more acute attacks of gout in the previous 2 years, with 35% (n = 7) of patients experiencing more than 5 acute attacks of gout within this period, despite being prescribed allopurinol.

Patients with renal impairment (estimated creatinine clearance < 50 ml/min) were started on a low dose of probenecid (250 mg daily, n = 5, Figure 1). One of these patients, who had tophaceous gout, had achieved the target plasma urate concentration of < 0.30 mmol/l before probenecid treatment but started probenecid because even lower plasma urate concentrations were considered benefi-

Table 1. Characteristics of the gouty patients who received probenecid (n = 20).

Characteristics	Mean (95% CI)
Age, yrs	59 (54–64)
Body mass index, kg/m ²	27.6 (25.5–29.7)
Estimated creatinine clearance, ml/min*	76.5 (65.5–87.6)
Plasma urate concentration at baseline taking allopurinol, mmol/l	0.37 (0.34–0.41)
History of gout, n (%)	
Duration of gout < 10 yrs	12 (60)
Presence of ≥ tophi	5 (30)
No. acute attacks in past 2 yrs	
0	4 (20)
1–3	6 (30)
4–5	3 (15)
> 5	7 (35)
Duration of allopurinol therapy < 5 yrs	12 (60)
Concomitant medications at study entry, n (%)	
No regular medicines	3 (17)
Aspirin 100 mg/day	3 (17)
Diuretics**	4 (22)
Warfarin	2 (11)
Angiotensin II receptor antagonists (no losartan)	3 (17)
β-adrenergic receptor antagonists	3 (17)
Angiotensin converting enzyme inhibitors	4 (22)
Calcium channel blockers	2 (11)
HMG-CoA reductase inhibitors	7 (39)

* Estimated using the Cockcroft-Gault equation using lean body weight.

** Diuretics include frusemide (n = 1) and hydrochlorothiazide (n = 3).

cial. The remaining 4 patients progressed to higher doses of probenecid. Thus, of the 20 patients who received the combination, 19 received 500 mg probenecid daily in addition to their fixed dose of allopurinol (Figure 1). Seven of these patients failed to achieve target plasma urate concentrations and, therefore, received higher doses of probenecid (1000 mg/day). The dose of probenecid was increased to 1500 mg/day in 3 of these patients and 1 patient failed to achieve the target plasma urate concentration on the maximal allowed dose of probenecid, 2 g daily. The increments in plasma oxypurinol and probenecid concentrations with all doses of medicines suggested our patients were adherent to their therapy.

Pharmacokinetics of oxypurinol. The addition of probenecid 500 mg/day to allopurinol therapy significantly decreased the average steady-state oxypurinol concentrations by 26% compared to allopurinol alone (Table 2). This is because probenecid significantly increased the apparent total, renal, and fractional renal clearances of oxypurinol by 35%, 27%, and 40%, respectively (Table 2). Doubling the dose of probenecid to 1000 mg daily (n = 7) did not alter the plasma concentrations of oxypurinol further when compared to the coadministration of allopurinol and 500 mg probenecid daily. However, the apparent, renal, and fractional renal clearances of oxypurinol increased by a further 8%, 27%,

Table 2. Pharmacokinetics of oxypurinol and the pharmacodynamic effects of allopurinol alone or with probenecid for at least 7 days (500 or 1000 mg/day) in patients with gout. Data are mean (95% CI).

Variable	Allopurinol, n = 19 [†]	Allopurinol and Probenecid (500 mg/day), n = 19	Allopurinol and Probenecid (1000 mg/day), n = 7
Plasma urate concentrations and renal and fractional renal clearances			
C _{UA} , mmol/l	0.37 (0.34–0.41)	0.28 (0.24–0.31)*	
CL _{R(UA)} , ml/min	6.0 (4.4–7.5)	9.6 (6.9–12.3)**	
CL _{R(CR)} , ml/min	125.0 (105.1–144.8)	109.1 (88.4–129.8)***	
CL _{R(UA/CR)} ratio	0.046 (0.038–0.054)	0.088 (0.072–0.104)*	
Plasma oxypurinol concentrations and total, renal, and fractional renal clearances			
C _{av,ss} , mg/l	11.1 (5.0–17.3)	8.2 (4.0–12.4)*	
CL/F, ml/min	16.2 (10.3–22.1)	21.9 (14.6–29.2)*	
CL _{R(OXY)} , ml/min	12.7 (9.8–15.6)	16.1 (12.3–19.9)***	
CL _{R(OXY/CR)} ratio	0.098 (0.083–0.114)	0.140 (0.117–0.163)*	
Patients who received both 500 mg and 1000 mg daily probenecid			
Plasma urate concentrations and renal and fractional renal clearances			
C _{UA} , mmol/l	0.43 (0.35–0.50)	0.34 (0.27–0.41)**	0.27 (0.21–0.34)**††
CL _{R(UA)} , ml/min	4.8 (1.8–7.8)	8.9 (4.0–13.8)**	10.4 (5.4–15.5)**
CL _{R(CR)} , ml/min	120 (70–171)	107 (59–155)	110 (66–155)
CL _{R(UA/CR)} ratio	0.038 (0.027–0.050)	0.089 (0.047–0.110)**	0.094 (0.053–0.136)**
Plasma oxypurinol concentrations and total, renal, and fractional renal clearances			
C _{av,ss} , mg/l	12.4 (3.2–21.6)	8.9 (2.9–14.9)***	8.7 (2.4–14.7)***
CL/F, ml/min	14.7 (7.4–22.0)	19.7 (11.3–28.2)**	21.3 (12.1–30.4)**
CL _{R(OXY)} , ml/min	10.0 (3.1–16.9)	12.9 (6.2–19.6)	16.5 (8.3–24.6)***#
CL _{R(OXY/CR)} ratio	0.082 (0.045–0.118)	0.116 (0.068–0.163)***	0.146 (0.098–0.194)**

Subscripts: oxypurinol (OXY), urate (UA), and creatinine (CR). C_{av,ss}: average steady-state plasma concentration derived from NONMEM (daily doses of allopurinol ranged from 100 to 300 mg/day); CL_R: renal clearance; CL_{R(OXY/CR)}: fractional renal clearance of oxypurinol; CL_{R(UA/CR)}: fractional renal clearance of urate; CL/F: apparent total body clearance of oxypurinol derived from NONMEM. * p < 0.001; ** p < 0.01; *** p < 0.05 versus allopurinol monotherapy; † one subject achieved plasma urate < 0.3 mmol/l with the addition of probenecid 250 mg/day. †† p < 0.01; # p < 0.05 versus allopurinol and probenecid 500 mg daily.

and 20%, respectively. The fractional renal clearances of oxypurinol and urate were highly correlated ($p < 0.001$, $r^2 = 0.52$; Figure 2).

In 1 patient, the concentrations of probenecid at 1000 mg and 1500 mg daily were lower than at 500 mg daily probenecid, indicating poor adherence. Otherwise the plasma probenecid concentrations for individuals across the doses of probenecid they received rose with dose, as expected (data not shown).

Pharmacodynamics. Overall, the plasma concentrations of urate decreased by 25% with the addition of probenecid (Table 2); the exception was 1 patient with tophaceous gout whose plasma urate increased slightly with addition of probenecid 500 mg/day (Figure 3). In 1 other patient, plasma concentrations of urate did not fall below 0.30 mmol/l despite adequate plasma concentrations of probenecid and oxypurinol. Patients with renal impairment ($n = 5$) showed similar reductions in plasma urate concentrations with the increases in probenecid dose compared to those with relatively good renal function (Figure 3). For the majority of patients ($n = 12$), the target plasma concentration of urate was reached with 500 mg probenecid per day. Seven




Figure 2. Relationship between the fractional renal clearance of oxypurinol and urate ($p < 0.001$, $r^2 = 0.52$). Closed circles represent allopurinol monotherapy, open circles allopurinol coadministered with probenecid (500 mg daily); crosses represent allopurinol coadministered with probenecid (1000 mg daily). Broken line represents the line of unity.




Figure 3. Plasma concentrations of urate in gouty patients ($n = 20$) during allopurinol monotherapy and with the addition of increasing doses of probenecid. Open symbols represent patients with creatinine clearance < 50 ml/min; closed symbols, patients with creatinine clearance > 50 ml/min. Allopurinol doses range from 100 to 400 mg/day: red, 100 mg/day; blue, 200 mg/day; black, 300 mg/day; green, 400 mg/day. Probenecid doses ranged from 250 to 2000 mg/day. Broken line represents the target plasma urate concentration of 0.30 mmol/l.

patients received doses of probenecid > 500 mg daily. These patients had higher plasma urate concentrations during allopurinol monotherapy [mean 0.42 mmol/l (95% CI 0.35–0.50)] compared to patients who required only up to 500 mg probenecid daily [$n = 13$; mean 0.34 mmol/l (95% CI 0.31–0.37)] ($p < 0.01$).

Consistent with the decreased plasma concentrations of urate, probenecid 500 mg/day increased the renal clearance of urate by 62% and the fractional renal clearance of urate by 91%. The reduction in plasma concentrations of urate was somewhat less than expected given the increase in the fractional renal clearance of urate. For patients who received both 500 mg and 1000 mg of probenecid daily ($n = 7$), the plasma concentrations of urate decreased by 21% and 37%, respectively, compared to allopurinol monotherapy. Correspondingly, the fractional renal clearance of urate increased by 57% and 60%, respectively. Interestingly, the fractional renal clearance of urate was less than 0.06 in the majority (68%) of patients in this study, indicative of the low urate clearance phenotype²⁵.

No patient in this study reported an adverse event; in particular, no attacks of acute gout were reported.

DISCUSSION

In this study, concomitant probenecid reduced plasma concentrations of urate below 0.30 mmol/l in all but one of

these 20 patients with gout. This is consistent with work in healthy volunteers^{18,21} and other patients with gout²⁶. We found that probenecid 500 mg/day was sufficient in 12 of the 20 patients, and that those patients with higher plasma urate concentrations during allopurinol monotherapy required higher doses of probenecid. We also found that probenecid was effective in our few patients with renal impairment (creatinine clearance < 50 ml/min).

The reductions in plasma urate concentration occurred despite the significant fall in plasma concentrations of oxypurinol due to the probenecid-induced increase in the renal clearance of oxypurinol. Thus the uricosuric effect of probenecid more than compensates for the probenecid-induced reduction in plasma concentrations of oxypurinol, consistent with our observations in healthy volunteers¹⁸. Our results are also consistent with studies of the combination of allopurinol and another uricosuric agent, benzbromarone, which also added to the hypouricemic effect of allopurinol, despite decreasing the plasma concentrations of oxypurinol^{21,27,28,29,30}.

The probenecid-induced increase in the renal clearance of both oxypurinol and urate is almost certainly due to inhibition of the reabsorption of the 2 compounds by the renal transporter URAT1. URAT1 is inhibited by probenecid and both urate and oxypurinol are substrates for URAT1^{19,31} consistent with their similar chemical structures. The linear

relationship between the fractional renal clearances of urate and oxypurinol (Figure 2) is also consistent with URAT1 being the major transporter of urate and oxypurinol.

The 25% and 37% average decrease in the plasma concentrations of urate with addition of probenecid at 500 mg and 1000 mg daily, respectively, to a stable allopurinol dosing regimen is similar to that reported by others. Reinders, *et al*¹⁹ found that coadministration of allopurinol and probenecid (1000 mg daily) in gouty patients with reasonable renal function (glomerular filtration rate > 50 ml/min) decreased plasma urate concentrations by a further 33% compared to allopurinol alone. By contrast, Yu, *et al*²⁰ reported only 10% reduction in plasma urate concentrations with the addition of probenecid to allopurinol therapy in patients with tophaceous gout. However, many of their patients had impaired renal function, which may explain the reduced hypouricemic effect of probenecid observed by these and other investigators^{13,32}. Only a small proportion of our patients (n = 5) had creatinine clearances below 50 ml/min. Nevertheless we observed an effect of concomitant probenecid in these 5 patients, albeit somewhat diminished relative to those with better renal function.

A notable finding of our study was that the decrease in plasma concentrations of urate with the combination was less than predicted from the nearly 2-fold increase in the fractional renal clearance of urate (Table 2). The renal clearance of urate accounts for only two-thirds of its total clearance, the remaining one-third being cleared by the gastrointestinal tract³³. By contrast, the decrease in plasma concentrations of oxypurinol was consistent with the changes observed in the fractional renal clearance of oxypurinol, suggesting that renal clearance accounts for the majority of its total clearance¹.

The patients participating in this study generally had been diagnosed with gout within the last decade and were not well controlled on allopurinol alone. Tophaceous deposits and acute attacks of gout were common. Patients commonly stated that they had missed an “occasional” dose of allopurinol prior to participation in this study whereas others described taking allopurinol “holidays.” In this cohort, the first step to better outcomes would be to optimize the use of allopurinol and more consistent adherence to the drug.

There are a number of possible approaches to reducing plasma urate concentrations to satisfactory levels in patients already taking allopurinol. Improving the adherence of the patient to allopurinol therapy is the first option. The next is to increase the dosage of allopurinol, above 300 mg/day if necessary, until target plasma concentrations of urate are achieved. Despite concerns that this approach may increase the chance of hypersensitivity reactions to the drug³⁴, other researchers have demonstrated that escalation of allopurinol dosage can be instituted safely and most patients can be treated successfully^{35,36}. This approach is preferred as it is

effective, safe, and less complicated for the patient. Another approach is to coprescribe probenecid (or benzbromarone if available) in addition to allopurinol to enhance the hypouricemic effect. Some rheumatologists select this approach when gout is not controlled or tophi are present. Although the combination has greater hypouricemic efficacy there are disadvantages. A second medication that is usually taken twice daily is a further challenge for patient adherence^{37,38}. Another approach would be to use an alternative hypouricemic drug. Uricosuric monotherapy is efficacious if the patient does not have significant renal impairment. The new xanthine oxidase inhibitor febuxostat, which has similar efficacy to allopurinol if dosage of the latter is optimized, can be used. Although febuxostat is expensive and not available in a number of countries, it is a useful alternative if the patient is intolerant of allopurinol³⁹.

We did not investigate the effect of oxypurinol on the pharmacokinetics of probenecid in detail. However, studies in healthy volunteers¹⁸ and hypertensive gouty patients¹⁷ clearly demonstrated that the addition of allopurinol to probenecid does not influence the pharmacokinetics of probenecid.

Our study demonstrated a significant pharmacokinetic and pharmacodynamic interaction between oxypurinol, the active metabolite of allopurinol, and probenecid. Coadministration of allopurinol and probenecid had a greater hypouricemic effect in gouty patients than allopurinol alone. Patients with renal impairment may still benefit from addition of probenecid to background treatment with allopurinol. This study, along with that of Reinders, *et al*¹⁹, establishes an additional treatment option for patients whose plasma urate concentrations are responding inadequately to allopurinol alone.

ACKNOWLEDGMENT

The authors thank Louise Greenup for help with patient recruitment and study visit coordination. They also thank the medical personnel involved in the study including Dr. Mona Manghani, Dr. Ed Park, Dr. Minh Duong, and Dr. Kevin Maruno.

REFERENCES

1. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. *Clin Pharmacokinet* 2007;46:623-44.
2. Walter-Sack I, de Vries JX, Kreiner C, Ittensohn A, Stenzhorn G, Voss A, et al. Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite? *Clin Invest* 1993;71:240-6.
3. Walter-Sack I, de Vries JX, Ernst B, Frei M, Kolb S, Kosmowski J, et al. Uric acid lowering effect of oxypurinol sodium in hyperuricemic patients — therapeutic equivalence to allopurinol. *J Rheumatol* 1996;23:498-501.
4. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. *Rheumatology* 2007;46:1372-4.
5. Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, et al. Optimal range of serum urate concentrations to minimize

- risk of gouty attacks during anti-hyperuricemic treatment. *Adv Exp Med Biol* 1998;431:13-8.
6. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. *Arthritis Rheum* 2004;51:321-5.
 7. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? *J Rheumatol* 2001;28:577-80.
 8. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. *Arthritis Rheum* 2002;47:356-60.
 9. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. *Nature* 2002;417:447-52.
 10. Robertson EE, Rankin GO. Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. *Pharmacol Ther* 2006;109:399-412.
 11. Gutman AB. Uricosuric drugs, with special reference to probenecid and sulfinpyrazone. *Adv Pharmacol* 1966;4:91-142.
 12. Garyfallos A, Magoula I, Tsapas G. Evaluation of the renal mechanisms for urate homeostasis in uremic patients by probenecid and pyrazinamide test. *Nephron* 1987;46:273-80.
 13. Bartels EC, Matossian GS. Gout: six-year follow-up on probenecid (benemid) therapy. *Arthritis Rheum* 1959;2:193-202.
 14. Thompson GR, Duff IF, Robinson WD, Mikkelsen WM, Galindez H. Long term uricosuric therapy in gout. *Arthritis Rheum* 1962;5:384-96.
 15. Lang F, Greger R, Oberleithner H, Griss E, Lang K, Pastner D, et al. Renal handling of urate in healthy man in hyperuricaemia and renal insufficiency: circadian fluctuation, effect of water diuresis and of uricosuric agents. *Eur J Clin Invest* 1980;10:285-92.
 16. Talbott JH. Treating gout: successful methods of prevention and control. *Postgrad Med* 1978;63:175-80.
 17. Tjandramaga TB, Cucinell SA, Israili ZH, Perel JM, Dayton PG, Yu TF, et al. Observations on the disposition of probenecid in patients receiving allopurinol. *Pharmacology* 1972;8:259-72.
 18. Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. *Clin Pharmacokinet* 2008;47:111-8.
 19. Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. *Clin Rheumatol* 2007;26:1459-65.
 20. Yu TF, Gutman AB. Effect of allopurinol (4-hydroxypyrazolo-(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary gout. *Am J Med* 1964;37:885-98.
 21. Yamamoto T, Moriwaki Y, Takahashi S, Suda M, Higashino K. Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol. *Ann Rheum Dis* 1991;50:631-3.
 22. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. *Arthritis Rheum* 1977;20:895-900.
 23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16:31-41.
 24. Stocker SL, Franklin ME, Anderson JM, Pillans PI, Williams KM, McLachlan AJ, et al. Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2010;878:2363-8.
 25. Graessler J, Graessler A, Unger S, Kopprasch S, Tausche AK, Kuhlisch E, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. *Arthritis Rheum* 2006;54:292-300.
 26. Elion GB, Yu TF, Gutman AB, Hitchings GH. Renal clearance of oxypurinol, the chief metabolite of allopurinol. *Am J Med* 1968;45:69-77.
 27. Mertz DP, Eichhorn R. Does benzbromarone in therapeutic doses raise renal excretion of oxypurinol? *Klin Wochenschr* 1984;62:1170-2.
 28. Muller FO, Schall R, Groenewoud G, Hundt HK, van der Merwe JC, van Dyk M. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. *Eur J Clin Pharmacol* 1993;44:69-72.
 29. Colin JN, Farinotti R, Fredj G, Tod M, Clavel JP, Vignon E, et al. Kinetics of allopurinol and oxypurinol after chronic oral administration. Interaction with benzbromarone. *Eur J Clin Pharmacol* 1986;31:53-8.
 30. Lartigue-Mattei C, Chabard JL, Ristori JM, Bussiere JL, Bargnoux H, Petit J, et al. Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry. *Fundam Clin Pharmacol* 1991;5:621-33.
 31. Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. *Drug Metab Dispos* 2005;33:1791-5.
 32. Mason RM. Benemid. *Proc R Soc Med* 1956;49:591-4.
 33. Sorensen LB, Levinson DJ. Origin and extrarenal elimination of uric acid in man. *Nephron* 1975;14:7-20.
 34. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. *Am J Med* 1984;76:47-56.
 35. Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. *Ann Rheum Dis* 2009;68:892-7.
 36. Stamp LK, O'Donnell JL, Zhang M, Frampton C, Barclay M, Chapman PT. Increasing allopurinol dose above the recommended range is effective and safe in chronic gout, including those with renal impairment — a pilot study [abstract]. *Arthritis Rheum* 2009;60 Suppl:1950.
 37. Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, et al. Adherence with urate-lowering therapies for the treatment of gout. *Arthritis Res Ther* 2009;11:R46.
 38. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. *Pharmacotherapy* 2008;28:437-43.
 39. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. *N Engl J Med* 2005;353:2450-61.